Format

Send to

Choose Destination
J Immunol Methods. 2011 Feb 28;365(1-2):1-7. doi: 10.1016/j.jim.2010.12.001. Epub 2010 Dec 13.

Potential therapeutic applications of antisense morpholino oligonucleotides in modulation of splicing in primary immunodeficiency diseases.

Author information

1
Department of Pathology and Laboratory Medicine, The David Geffen School of Medicine at UCLA, CA 90095-1732, USA. Ldu@mednet.ucla.edu

Abstract

Highly complementary antisense morpholino oligonucleotides (AMOs) can bind to pre-mRNA and modulate splicing site selection. This offers a powerful tool to regulate the splicing process, such as correcting subtypes of splicing mutations and nonsense mutations and reprogramming alternative splicing processes. Therefore, AMO-mediated splicing modulation represents an attractive therapeutic strategy for genetic disorders. Primary immunodeficiency diseases (PIDs) are a heterogeneous group of genetic disorders that result from mutations in genes involved in development and maintenance of the immune system. Many of these mutations are splicing mutations and nonsense mutations that can be manipulated by AMOs. This review discusses AMO-mediated splicing modulation approaches and their potential applications in treating PIDs.

PMID:
21147113
PMCID:
PMC3061259
DOI:
10.1016/j.jim.2010.12.001
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center